[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-hodgkin-lymphoma-nhl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-hodgkin-lymphoma-nhl":238},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,49,80,114,143,168,193,214],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100629759",false,"NCT07478848","Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas","A Pilot Trial of Bridging Radiation Therapy With Oral Vancomycin for Patients With B-cell Lymphomas Undergoing CAR-T Therapy","Inclusion Criteria:\n\n* Male or female subject aged ≥ 18 years.\n* Pathologically confirmed B-cell lymphoma patients intended for standard of care CAR-T\n* ECOG Performance Status ≤ 2.\n* Subjects must be clinically eligible to receive standard of care anti-CD19 CAR-T\n* Subjects must have at least one site of disease amenable to radiation, with the ability to deliver radiation to at least 50% of involved sites\n* Subjects must have at least one site of measurable disease based on CT or FDG PET\n* Subjects must not be anticipated to require additional therapy beyond bridging radiation listed in this protocol for control of their lymphoma\n* For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause.\n\nThe following age-specific requirements apply:\n\nWomen \\\u003C 50 years of age: amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n\nWomen ≥ 50 years of age: amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or had radiation-induced menopause with last menses \\>1 year ago; or had chemotherapy-induced menopause with last menses \\>1 year ago; or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).\n\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Unable to take oral vancomycin for any reason, including: Allergy or Inability to swallow drug\n* Known history of vancomycin resistant enterococcus (VRE)\n* Contraindications to radiation therapy, including scleroderma, systemic lupus erythematosus, Crohn disease, ulcerative colitis, or idiopathic pulmonary fibrosis\n* History of radiation pneumonitis or other grade 4 radiation-related adverse event\n* Prior or concurrent malignancy whose natural history or treatment which has the potential to interfere with the safety or efficacy assessment of the radiation therapy are eligible for this trial.\n* Severe, uncontrolled, significant intercurrent or recent illness that would exclude them from being a candidate for standard-of-care CART therapy.\n* Known uncontrolled HIV infection with a detectable viral load at the time of screening. Note: Patients on effective antiretroviral therapy or who will plan on going on antiretroviral therapy at the time of screening are eligible for this trial. HIV testing is not required for eligibility.\n* Active infection that required the use of antibiotics within 4 weeks prior to registration\n* Any other condition that would, in the investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures","ALL","18 Years",{"count":18,"type":19},14,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This clinical trial assesses whether it is feasible to use radiation therapy with vancomycin prior to CAR T-cell therapy for patients with large B-cell lymphomas",[25,26,27,28,29],"Large B Cell Lymphoma","Non Hodgkin Lymphoma (NHL)","Diffuse Large B Cell Lymphoma (DLBCL)","Diffuse Large B Cell Lymphoma Refractory","Diffuse Large B Cell Lymphoma Relapsed",[31,32,33,34,35],"non-hodgkin lymphoma","NHL","large B cell lymphoma","DLBCL","diffuse large B cell lymphoma","RECRUITING","2026-06-29",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":42,"type":40},"2026-05-29",{"date":44,"type":19},"2029-01-01",{"name":46,"class":47},"Abramson Cancer Center at Penn Medicine","OTHER",1,{"id":50,"slug":4,"hasResults":10,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100632795","NCT07518329","Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.","A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells in Patients With CD19+ Non-Hodgkin Lymphoma and Leukemia","Inclusion Criteria:\n\n* Over 18 years old\n* Confirmed Diagnoses of Confirmed diagnosis of CD19+ non-Hodgkins lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphatic Leukemia or Hairy Cell Leukemia\n* Life Expectancy greater than 3 months\n* Adequate Hepatic and Renal Function\n* Adequate Bone Marrow Function\n* Adequate ECG Vales\n* Agree to use appropriate contraception to avoid becoming pregnant for up to 12 months post treatment and agree not to donate sperm or ova for 12 months post treatment\n\nExclusion Criteria:\n\n* Prior anti-CD1d monoclonal antibody treatment\n* Prior allogeneic stem cell transplant except where the participant is greater than 100 days and does not have Graft Versus Host Disease (uncontrolled)\n* Prior Organ Transplant\n* Previous Malignancy in last 3 years that's active or been treated.\n* Current central nervous system involvement by lymphoma or leukaemia\n* Evidence of Cardiac Dysfunction\n* Active Autoimmune disease requiring systemic immunosuppressive therapy within the past 6 months.\n* Known active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.\n* History of Graft Vs Host Disease Grade 2 to 4\n* No active Graft Vs Host Disease following a minimum of 3 months withdrawal from all Graft Vs Host Disease treatments\n* Must not have received systemic anti-cancer therapy for the underlying malignancy within 6 weeks prior to the start of conditioning chemotherapy on Day -6.\n* Participants that have received autologous or allogenic CAR-T cell therapy within 3 months prior to commencing screening.\n* Use of systemic corticosteroids within 15 days of commencement of conditioning chemotherapy on Day -6 or other immunosuppressive drugs within 30 days\n* Recent major surgery (within 4 weeks prior to commencement of conditioning chemotherapy on Day -6) or planned major surgery within 8 weeks following ALA-101 infusion on Day 1.\n* Active infection requiring intravenous antibiotic, antifungal, or antiviral medication or hospital admission within 10 days prior to commencement of conditioning chemotherapy on Day -6\n* Severe (e.g., severe chronic obstructive pulmonary disease, severe Parkinson's disease) or poorly controlled (e.g., hypertension, diabetes, active inflammatory bowel disease) medical condition.\n* Vaccinated with a live vaccine within 28 days prior to commencement of conditioning chemotherapy on Day -6 or planned live vaccination within 6 months following ALA-101 infusion.\n\nAdditional criteria apply.",{"count":56,"type":19},46,[22],"Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101",[26,60],"Leukaemia",[62,63,64,65,66,67],"C19+","Lymphoma","Leukemia","CART T CELL","iNKT","CAR iNKT","NOT_YET_RECRUITING","2026-04-06",{"date":71,"type":40},"2026-04-08",{"date":73,"type":19},"2026-04-01",{"date":75,"type":19},"2030-08-30",{"name":77,"class":78},"Arovella Therapeutics Ltd","INDUSTRY",3,{"id":81,"slug":4,"hasResults":10,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":20,"phases":89,"briefSummary":91,"conditions":92,"keywords":100,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":48},"100376822","NCT04186520","CAR-20\u002F19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","Phase I\u002FII Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and\u002For Refractory B Cell Malignancies","GENERAL INCLUSION CRITERIA FOR ALL PATIENTS\n\n1. Patients must be aged ≥18 years and ≤80 years with relapsed or refractory B-cell non-Hodgkin Lymphoma.\n2. Absolute cluster of differentiation 3 (CD3) count ≥50 mm\\^3.\n3. Magnetic resonance imaging (MRI) brain and lumbar puncture with cerebrospinal fluid (CSF) analysis by cytology and flow cytometry without evidence of central nervous system (CNS) involvement ONLY in patients with history of CNS involvement or clinical suspicion at the time of enrollment EXCEPT Arm E subjects.\n4. Measurable disease must be documented within four weeks of the time of consent defined as nodal lesions greater than 15 mm in the long axis or extranodal lesions \\>10 mm in long and short axis OR bone marrow involvement that is biopsy proven for B-cell NHL (see separate criteria for CLL and primary\u002Fsecondary CNS lymphoma).\n5. Karnofsky performance score ≥70.\n6. Adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C5 x upper limit of normal (ULN); serum bilirubin and alkaline phosphatase \\\u003C5 x ULN, or considered not clinically significant as per the clinical PIs discretion (e.g. Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.\n7. ANC≥1000 with no G-CSF within 72 hours or pegylated G-CSF within 14 days.\n8. Platelets≥50,000 with no transfusion within 72 hours.\n9. Adequate renal function, defined as creatinine clearance \\>60 ml\u002Fmin AND serum Cr≤1.5 mg\u002FdL.\n\n   a. No IV hydration within 24 hours of eligibility. b. No dialysis dependent renal failure within three months of planned CAR infusion.\n10. Able to provide written informed consent.\n11. Agree to practice birth control during the study.\n12. Adequate cardiac function as indicated by New York Heart Association (NYHA) classification I or II AND left ventricular ejection fraction of ≥45% (by cardiac echocardiogram (ECHO) or multigated acquisition scan (MUGA)) and adequate pulmonary function as indicated by room air oxygen saturation of ≥92%.\n13. Expected survival \\>12 weeks.\n14. Negative urine or serum pregnancy test in females of child bearing potential at study entry.\n15. Meet criteria regarding fertility and contraception.\n16. No contraindication to central line access.\n17. Patient has demonstrated compliance to other therapies.\n\nPhase 1: 3+3 COHORT ELEGIBILITY CRITERIA\n\n1. Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), Mantle Cell Lymphoma, and DLBCL with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).\n2. Patients must have active, measurable disease as defined and meet one of the following criteria.\n\n   1. Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant.\n   2. Relapse post-autologous transplant\n   3. Relapse post-allogeneic transplant\n   4. Patients not previously treated with CAR-T cell therapy\n\nPHASE 1b and 2 COHORT ELEGIBILITY CRITERIA\n\nARM A: Six to nine patient expansion with 8-day manufacturing (Phase 1b)\n\n1. Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), and DLBCL with associated subtypes (aggressive B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, EBV+ diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).\n2. Patients must have active, measurable disease as defined and meet one of the following criteria:\n\n   1. Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant.\n   2. Relapse post-autologous transplant.\n   3. Relapse post-allogeneic transplant.\n   4. Relapse post-anti-cluster of differentiation 19 (CD19) CAR-T cell therapy.\n\n   i. A maximum of two patients with prior CAR-T will be allowed in this cohort.\n\nARM B: Six to nine patient expansion with 12-day manufacturing (Phase 1b)\n\n1\\. Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), and DLBCL with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, EBV+ diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).\n\n2\\. Patients must have active, measurable disease as defined and meet one of the following criteria:\n\n1. Must have received Rituximab or another CD20 antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant.\n2. Relapse post-autologous transplant.\n3. Relapse post-allogeneic transplant.\n4. Relapse post-anti-CD19 CAR-T cell therapy.\n\ni. A maximum of two patients with prior CAR-T will be allowed in this cohort.\n\nARM C: 24 patient cryopreservation 8\u002F12 flexible manufacturing arm\n\n1. Diagnosis of B-cell NHL including Follicular Lymphoma, Marginal Zone Lymphoma (splenic, nodal, extranodal), and DLBCL with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, EBV+ diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation).\n2. Patients must have active, measurable disease as defined and meet one of the following criteria a. Must have received Rituximab or another CD20 antibody and at minimum two different chemotherapy regimens appropriate for their disease and be ineligible to receive autologous transplant b. Relapse post-autologous transplant c. Relapse post-allogeneic transplant d. Relapse post-anti-CD19 CAR-T cell therapy i. A maximum of 2 patients with prior CAR-T will be allowed in this cohort\n\nARM D: Phase 1 and Phase 1b: CLL\n\n1\\. Diagnosis of B-cell CLL or small lymphocytic leukemia (SLL) 2. Failed\u002Fprogressed or been intolerant to two prior lines of therapy one of which MUST be either a covalent BTK inhibitor (e.g. ibrutinib, acalabrutinib, zanabrutinib, etc) or BCL2 inhibitors (e.g. venetoclax or other investigational BCL2) 3. Indication for treatment as defined as any of the following:\n\n1. measurable lymph nodes ≥ 1.5 cm in the greatest transverse diameter and\u002For hepatomegaly or splenomegaly)\n2. bone marrow involvement with ≥10% CLL involvement\n\nARM E: Phase 1 and Phase1b Relapsed\u002FRefractory Primary or Secondary CNS Lymphoma\n\n1. Diagnosis of diffuse large B cell lymphoma (DLBCL) with associated subtypes (aggressive B-cell lymphoma, high grade B-cell lymphoma, T-cell\u002Fhistocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, EBV+ diffuse large B-cell lymphoma, transformed lymphoma such as transformed follicular or marginal zone, and Richter's transformation) with secondary CNS lymphoma involvement OR primary CNS lymphoma.\n2. For Primary CNS lymphoma, relapsed or refractory following at least one line of CNS-directed therapy.\n3. Secondary CNS lymphoma relapsed or refractory following at least one line of CNS-directed therapy for treatment of CNS lymphoma.\n\n   1. For patients with secondary central nervous system lymphoma (CNSL) with concurrent systemic lymphoma, the concurrent systemic lymphoma must have relapsed following at least 1 prior line of therapy (which must have included an anti-CD20 monoclonal antibody and an anthracycline)\n4. Measurable CNS disease by either lumbar puncture (LP) with positivity in CNS by flow cytometry or morphology for lymphoma cells OR magnetic resonance imaging (MRI) with enhancing lesions ≥1 cm in size consistent with lymphoma\n5. Must have had prior treatment with high dose methotrexate defined as methotrexate given intravenously at a dose ≥2500 mg\u002Fm\\^2 and either progression\u002Frelapse, stable disease, or intolerance to at least one cycle of treatment.\n\nPhase II Cohort: Mantle Cell Lymphoma\n\n1\\. Diagnosis of Mantle Cell Lymphoma. 2. Patients must have active, measurable disease as previously defined and have relapsed, refractory disease as defined as one of the following:\n\n1. Relapsed disease after two lines of cytotoxic chemotherapy including administration of anti-CD20 antibody.\n2. Progressive disease after ≥second line Bruton tyrosine kinase (BTK) inhibitor.\n3. Relapse post-autologous transplant.\n4. Relapse post-allogeneic transplant.\n5. Relapse post anti-CD19 CAR-T cell therapy.\n\ni. A maximum of four patients with history of prior anti-CD19 CAR-T will be allowed in this cohort.\n\nEXCLUSION CRITERIA (ALL PATIENTS)\n\nA potential subject who meets any of the following exclusion criteria is ineligible to participate in the study.\n\n1. Positive beta- human chorionic gonadotropin (HCG) in female of childbearing potential.\n2. Confirmed active human immunodeficiency virus (HIV), Hepatitis B or C infection.\n3. History of significant autoimmune disease OR active, uncontrolled autoimmune phenomenon requiring steroid therapy defined as \\>20 mg of prednisone or equivalent daily.\n4. Presence of ≥grade 3 non-hematologic toxicities as per CTCAE version 5.0 from any previous treatment unless it is felt to be due to underlying disease.\n5. Concurrent use of investigational therapeutic agents or enrollment on another therapeutic clinical trial at any institution. Minimum of 14 days or 5 half-lives of the drug (whichever is shorter) washout prior to apheresis.\n6. Refusal to participate in the long-term follow-up protocol\n7. Patients with active CNS involvement by malignancy on MRI or by lumbar puncture (Not applicable to Arm E cohort.)\n\n   a. Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was \\>4 weeks before enrollment and a remission documented within 8 weeks of planned CAR-T cell infusion by MRI brain and CSF analysis.\n8. Previous recipients of allogeneic hematopoietic stem cell transplantation (AHCT) are excluded if they are \\\u003C100 days' post-transplant, have evidence of active graft-versus-host-disease (GVHD) of any grade, or are currently on immunosuppression.\n9. Prior allogeneic CAR T-cell therapy\n10. Previous recipients of autologous CAR-T cell therapy directed at either CD19 or CD20 are excluded if they are \\\u003C100 days post prior CAR-T cell treatment (does not include re-enrollment) or have \\>5% residual circulating CAR-T as measured by flow cytometry using a CD19 CAR detection reagent (Miltenyi Biotec)\n\n    a. Patients with prior CAR-T treatment against CD19 or CD20 must have repeat biopsy post-CAR-T cell therapy confirming a minimum of 5% CD19 or CD20 positivity by immunohistochemistry or flow cytometry\n11. Anti-CD20 antibody treatment within 4 weeks of cell infusion\n12. Anti-CD19 antibody treatment within 4 weeks of cell infusion\n13. Cytotoxic chemotherapy other than lymphodepletion within 14 days of CAR-T cell infusion\n14. Cytotoxic chemotherapy treatment within 14 days or steroid treatment (other than replacement dose steroids) within 7 days prior to apheresis collection for CAR-T cells\n15. Oral chemotherapeutic agents or antibody directed treatment within 7 days of apheresis\n\n    a. BTK inhibitors are allowed until 1-day prior to apheresis and can re-start until 1-day prior to lymphodepletion\n16. Patients post solid organ transplant who develop high grade lymphomas or leukemias\n17. Concurrent active malignancy other than basal or squamous cell carcinomas of the skin (underlying low-grade lymphoma chronic lymphocytic leukemia\u002Ffollicular lymphoma (FL)\u002Fmarginal zone lymphoma (MZL) is allowable in patients with transformed large cell lymphoma)\n\nSPECIAL CRITERIA REGARDING FERTILITY AND CONTRACEPTION\n\nFemale subjects of reproductive potential (women who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within the preceding 24 months, or have not undergone a sterilization procedure \\[hysterectomy or bilateral oophorectomy\\]) must have a negative serum or urine pregnancy test performed as part of eligibility criteria Due to the high-risk level of this study, while enrolled, all subjects must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). Additionally, if participating in sexual activity that could lead to pregnancy, the study subject must agree to use reliable and double barrier methods of contraception during the follow-up period of the protocol.\n\nAcceptable birth control includes a combination of two of the following methods:\n\n* Condoms (male or female) with or without a spermicidal agent.\n* Diaphragm or cervical cap with spermicide\n* Intrauterine device (IUD)\n* Hormonal-based contraception Subjects who are not of reproductive potential (women who are premenarche or have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy tubal ligation, salpingectomy, and\u002For bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraception","80 Years",{"count":88,"type":19},100,[22,90],"PHASE2","This is a Phase I\u002FII, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7\u002FIL-15) manufactured chimeric antigen receptor (CAR)-20\u002F19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.",[26,93,94,95,96,97,98,99],"Mantle Cell Lymphoma (MCL)","Chronic Lymphocytic Leukemia (CLL)","Follicular Lymphoma","Marginal Zone Lymphoma","Diffuse Large B Cell Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Central Nervous System Lymphoma",[101,102,103,104],"CAR-T","Chimeric antigen receptor T-cell therapy","CAR Therapy","B-cell Malignancies","2026-02-19",{"date":107,"type":40},"2026-02-23",{"date":109,"type":40},"2020-05-18",{"date":111,"type":19},"2029-02-28",{"name":113,"class":47},"Medical College of Wisconsin",{"id":115,"slug":4,"hasResults":10,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":10,"sex":15,"minAge":121,"maxAge":86,"enrollmentInfo":122,"targetDuration":4,"studyType":20,"phases":124,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100601736","NCT07114367","NB02(POSELTINIB) Monotherapy in R\u002FR Non-Hodgkin's Lymphoma","An Open-Label, Multicenter, Monotherapy, Dose-Escalation, Phase 1 Clinical Trial of NB02 (Posseltinib) in Patients With Relapsed\u002FRefractory Non-Hodgkin's Lymphoma","POTENTIAL-M","Inclusion Criteria:\n\n1. Age 19 to 80 years.\n2. Patients must voluntarily agree to participate in the study and provide written informed consent prior to any study-related procedures.\n3. Patients with histologically confirmed follicular lymphoma, mantle cell lymphoma or marginal zone lymphoma.\n4. relapsed\u002Frefractory Patients who have received more than two prior lines of therapy.\n5. Measurable disease based on Lugano classification.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.\n7. Adequate organ function including:\n\nExclusion Criteria:\n\n1. Previous treatment with NB02 (poseltinib).\n2. Patients who have experienced progression on BTKi mono or BTKi containing regimen (However, patients who discontinued treatment due to adverse-effect-related intolerance or for economic or social reasons remain eligible for enrollment).\n3. Unable to take oral medication.\n4. Inability to comply with study and follow-up procedures.\n5. Concurrent use of other investigational drugs or enrollment in another clinical trial within 4 weeks prior to study drug administration.\n6. Patients who have previously been treated with NB02 (poseltinib) or any other BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib).\n7. Known HIV, HCV and HBV infection with active diseases","19 Years",{"count":123,"type":19},9,[22],"This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed\u002Frefractory NHL including FL, MCL and MZL",[26],[128,129,63,32,130,131,132],"Relapsed","Refractory","FL","MCL","MZL","2026-01-28",{"date":135,"type":40},"2026-01-30",{"date":137,"type":40},"2025-12-02",{"date":139,"type":19},"2027-12-31",{"name":141,"class":78},"NOBO Medicine",6,{"id":144,"slug":4,"hasResults":10,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":20,"phases":151,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":48},"100616977","NCT07312630","Clinical Study of LV009 Injection for the Treatment of Relapsed\u002FRefractory CD19-Positive Hematologic and Lymphoid Malignancies","Inclusion Criteria:\n\n* Age 18 to 70 years old (inclusive of both age limits), no gender restrictions, no racial restrictions\n* Expected survival time exceeds 12 weeks\n* ECOG performance status 0-2\n* Meets the NCCN guidelines' criteria for recurrence\u002Frefractory disease and is diagnosed with CD19-positive hematologic malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)\n* Liver and kidney function, as well as cardiopulmonary function, meet requirements.\n* Absolute lymphocyte count ≥ 0.5 × 10⁹\u002FL; platelet count ≥ 50 × 10⁹\u002FL; CD3-positive T cells ≥ 150 cells\u002FμL.\n* Subjects must have a body temperature ≤ 38°C (excluding tumor fever) within 24 hours prior to study drug infusion and must not have significant active infection.\n* Within 5 days prior to the study drug infusion, subjects must not receive therapeutic doses of corticosteroids (\\>5 mg\u002Fday of prednisone or other equivalent doses of corticosteroids) or other immunosuppressive agents.\n\nExclusion Criteria:\n\n* Patients deemed by the investigator to require long-term use of immunosuppressive agents during screening should be excluded.\n* Patients who have experienced a cerebrovascular accident or seizure within the six months prior to signing the informed consent form must be excluded.\n* Patients with malignant tumors other than the study disease must be excluded (only patients with carcinoma in situ may be considered for inclusion).\n* Hepatitis B surface antigen (HBsAg) positive; Hepatitis B core antibody (HBcAb) positive with peripheral blood hepatitis B virus (HBV) DNA titer outside normal reference range; Hepatitis C virus (HCV) antibody positive with peripheral blood hepatitis C virus (HCV) RNA positive; Human Immunodeficiency Virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Syphilis positive. (Patients meeting any criterion in this section must be excluded.)\n* Patients with severe cardiac conditions must be excluded, including but not limited to: unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \\[NYHA\\] class ≥ III), and severe arrhythmias.\n* Patients judged by the investigator to have unstable systemic diseases must be excluded, including but not limited to those with severe liver, kidney, or metabolic diseases requiring medication.\n* Patients with chronic progressive neurological diseases should be excluded.\n* Patients who have not recovered from acute toxic effects following prior treatment must be excluded.\n* Patients with active infections requiring systemic treatment or uncontrolled infections should be excluded (patients with mild urogenital tract infections and upper respiratory tract infections may be considered for inclusion).","70 Years",{"count":150,"type":19},19,[152],"EARLY_PHASE1","Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed\u002Frefractory CD19-positive hematologic malignancies.",[155,156],"Non-Hodgkin Lymphoma (NHL)","Acute Lymphoblastic Leukemia (ALL), Adult",[158,101],"CD19","2025-12-16",{"date":161,"type":40},"2025-12-31",{"date":163,"type":40},"2025-09-25",{"date":165,"type":19},"2027-12-12",{"name":167,"class":78},"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",{"id":169,"slug":4,"hasResults":10,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":20,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":189,"leadSponsor":191,"locationsCount":48},"100600762","NCT07101705","An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed\u002FRefractory Hematological Malignancies","Inclusion Criteria:\n\n1. Aged 18 - 75 years.\n2. ECOG scores 0-1.\n3. Expected survival time ≥ 12 weeks.\n4. Have a record of confirmed multiple myeloma (MM) according to IMWG criteria, or a record of histologically confirmed aggressive B-cell non-Hodgkin lymphoma (B-NHL). According to the definition of the 2022 World Health Organization (WHO) classification, the pathological types of aggressive B-NHL include: diffuse large B-cell lymphoma, not otherwise specified; diffuse large B-cell lymphoma\u002Fhigh-grade B-cell lymphoma with MYC and BCL2 rearrangements; high-grade B-cell lymphoma, not otherwise specified; primary mediastinal B-cell lymphoma; mantle cell lymphoma; grade 3b follicular lymphoma; large B-cell lymphoma transformed from indolent B-NHL.\n5. For MM subjects only: (1) Have received at least 2 lines of anti-tumor therapy, with each line of therapy undergoing at least one complete treatment cycle, and have experienced disease progression during or within 12 months after the last treatment; or be judged by the investigator as double-refractory to immunomodulators and proteasome inhibitors, and did not achieve a minimal response (MR) or better during the last treatment or experienced disease progression within 60 days after the end of treatment. (2) Have measurable lesions during the screening period, meeting any of the following criteria: (a) Serum M-protein ≥ 0.5 g\u002FdL; (b) Urine M-protein≥ 200 mg\u002F24h; (c) Involved free light chain (FLC) level ≥10 mg\u002FdL provided serum FLC ratio is abnormal; (d) Plasma cell percentage ≥30% detected by bone marrow aspirate\u002Fbiopsy; (e) Presence of at least one extramedullary lesion with a maximum diameter ≥ 2 cm.\n6. For aggressive B-NHL subjects only: (1) Have received at least 2 lines of anti-tumor therapy, and are refractory to the last line of therapy (at least 2 cycles) (best response is PD or SD) or have experienced disease progression after the end of treatment. Previous treatments must include standard treatment regimens with anti-CD20 monoclonal antibodies (except for subjects with CD20-negative tumors) and anthracyclines; (2) Have at least one measurable lesion during the screening period: lymph node lesions must have a longest diameter \\> 1.5 cm, and extranodal lesions must have a longest diameter \\> 1.0 cm.\n7. Hemogram meets the following requirements:\n\n   * Hemoglobin ≥ 6 g\u002FdL (no red blood cell transfusion within 1 week prior to screening, recombinant human erythropoietin is permitted);\n   * Absolute neutrophil count (ANC) ≥ 750 \u002FμL (no granulocyte colony-stimulating factor (G-CSF) used within 1 week prior to screening or no pegylated G-CSF used within 2 weeks prior to screening);\n   * Platelet count ≥ 50,000 \u002FμL;\n   * Lymphocyte count ≥ 500 \u002FμL.\n8. Renal function: Creatinine clearance (CrCl) (Modification of Diet in Renal Disease (MDRD) formula) ≥ 40 mL\u002Fmin\u002F1.73m² (for MM subjects with CrCl \\\u003C 40 mL\u002Fmin\u002F1.73m², the investigator can decide whether to enroll based on clinical indications).\n9. Liver function: Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3.0 × upper limit of normal (ULN), total bilirubin ≤ 1.5 × ULN (for subjects with Gilbert's syndrome or liver invasion by tumor, ALT and AST ≤ 5.0 × ULN and total bilirubin ≤ 3 × ULN are permitted).\n10. Cardiac function: Left ventricular ejection fraction ≥ 45%.\n11. Pulmonary function: Pulse oxygen saturation ≥ 92% without oxygen inhalation.\n12. Women with childbearing potential must have a negative blood pregnancy test and not be in the lactation period.\n13. Men and women with childbearing potential must agree to use effective contraceptive measures from the time of signing the informed consent form (ICF) until 1 year after the investigational drug administration.\n14. Men and women with childbearing potential must agree not to donate reproductive cells such as sperm or eggs (oocytes) from the time of signing the ICF until 1 year after the investigational drug administration.\n15. The participant or their legally authorized representative agrees to participate in this clinical trial and signs the ICF, indicating that he\u002Fshe understands the objective and procedures of this clinical trial and is willing to participate in the study.\n\nExclusion Criteria:\n\n1. The subject has received the following therapy prior to signing the ICF:\n\n   * Small molecule targeted therapy, epigenetic therapy, or treatment with an investigational drug or used an invasive investigational medical device within 14 days or at least 5 half-lives, whichever is longer;\n   * Immunosuppressive agent therapy (such as tacrolimus, mycophenolate mofetil, etc.) within 28 days;\n   * Monoclonal antibody treatment within 21 days;\n   * Cytotoxic therapy within 14 days;\n   * Proteasome inhibitor therapy within 14 days;\n   * Immunomodulator agent therapy within 7 days;\n   * Therapeutic dose of corticosteroids (defined as prednisone ≥ 20 mg\u002Fday or equivalent dose of other corticosteroids) within 72 hours, but physiological replacement dose, topical and inhaled corticosteroids are permitted;\n   * Radiotherapy within 28 days (only for subjects whose radiation field covers \\> 5% of bone marrow reserve).\n2. Received autologous hematopoietic stem cell transplantation within 24 weeks prior to signing the ICF.\n3. Received organ transplantation or allogeneic hematopoietic stem cell transplantation.\n4. Have other malignant tumors prior to screening, except for the following cases: malignant tumors that have received radical treatment and have no known active disease within 2 years prior to screening; or adequately treated non-melanoma skin cancer with no evidence of active disease.\n5. Previously treated with any viral therapy using vesicular stomatitis virus G (VSVG)-pseudotyped virus.\n6. Known active central nervous system involvement or clinical signs of meningeal involvement.\n7. Complicated with severe uncontrolled active infections (bacterial, viral, fungal, etc.).\n8. Have active autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) or diseases requiring systemic application of immunosuppressive drugs.\n9. Have hereditary bleeding\u002Fcoagulation diseases, other diseases that may increase the risk of bleeding, etc.\n10. Have active deep vein thrombosis (cancer emboli or thrombus) or pulmonary embolism within 12 weeks prior to signing the ICF, but if the investigator judges that the thrombus has been clinically treated and has no risk of detachment, enrollment is permitted.\n11. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood hepatitis B virus (HBV) DNA titer exceeding the normal range; positive for hepatitis C virus (HCV) antibody with peripheral blood hepatitis C virus (HCV) RNA titer exceeding the normal range; positive for human immunodeficiency virus (HIV) antibody; positive for syphilis test.\n12. Complicated with symptomatic heart failure or other severe cardiac diseases such as arrhythmia:\n\n    * New York Heart Association (NYHA) class III or IV congestive heart failure;\n    * Myocardial infarction, coronary artery bypass grafting (CABG) or coronary stent implantation within 24 weeks prior to signing the ICF;\n    * Clinically significant ventricular arrhythmia, or history of unexplained syncope (except those caused by vasovagal or dehydration);\n    * Significant non-ischemic cardiomyopathy history.\n13. Have other clinically significant diseases, including:\n\n    * Primary immunodeficiency;\n    * Stroke or epileptic seizure within 24 weeks prior to signing the ICF;\n    * Obvious clinical evidence of dementia or mental status changes;\n    * History of Parkinson's disease or Parkinson-like movement disorders.\n14. Underwent surgery within 2 weeks prior to signing the ICF or plan to undergo surgery within 2 weeks after drug administration, except for surgery under local anesthesia.\n15. Used attenuated\u002Finactivated vaccines within 28 days prior to signing the ICF.\n16. Known severe allergic reaction to OriV508 or its formulation components.\n17. Known severe allergic reaction to tocilizumab.\n18. Inability to establish venous access.\n19. Other situations deemed unsuitable for participating in the study by the investigator.","75 Years",{"count":175,"type":19},40,[152],"This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed\u002Frefractory hematological malignancies.",[179,155],"Multiple Myeloma (MM)",[181,182,183,184],"BCMA\u002FCD19","multiple myeloma","Non-Hodgkin lymphoma","In vivo CAR-T","2025-09-08",{"date":187,"type":40},"2025-09-09",{"date":185,"type":40},{"date":190,"type":19},"2028-08-01",{"name":192,"class":47},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":194,"slug":4,"hasResults":10,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":148,"enrollmentInfo":199,"targetDuration":4,"studyType":20,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":48},"100565748","NCT06646211","High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)","A Single-arm, Multicenter Phase Ⅱclinical Study Evaluating High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed Central Nervous System Diffuse Large B-cell Lymphoma (MTZ)","Inclusion Criteria:\n\n1. Men and woman who are 18 to 70 years of age\n2. Histologically documented PCNSL\n3. ECOG performance status ≤ 2\n4. Life expectancy of \\> 3 months\n5. Imaging show at least one measurable lesion in the central nervous system.\n6. Adequate bone marrow and organ function shown by:\n7. Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL\n8. Platelets ≥ 75 x 10\\^9\u002FL and no platelet transfusion within the past 14 days\n9. Hemoglobin (Hgb) ≥ 8 g\u002FdL and no red blood cell (RBC) transfusion within the past 14 days\n10. International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal\n11. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN\n12. Serum bilirubin ≤ 1.5×ULN\n13. Serum creatinine ≤ 2×ULN\n14. Lipase ≤ 1.5 x LUN\n15. Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of medication; women who are pregnant or breastfeeding are not eligible to participate in this study. Women of childbearing potential: from the time of signing the Informed Consent Form (ICF) until 30 days after the study ends, sexually active men: from the time of signing the ICF until 90 days after the study ends, must use contraceptive measures.\n16. Must be able to tolerate MRI\u002FCT scans\n17. Must be able to tolerate lumbar puncture and\u002For Ommaya tap\n\nExclusion Criteria:\n\n1. Diagnosed with a malignant tumor other than PCNSL or has received treatment, except for the following cases:\n\n   1. Received curative treatment and has no known active disease at least 3 years or more before screening for enrollment.\n   2. Fully treated non-melanoma skin cancer or malignant lentigo, with no evidence of disease.\n   3. Fully treated carcinoma in situ, with no evidence of disease currently.\n2. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure (New York Heart Association \\> Class 2), unstable angina, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification\n3. Uncontrolled hypertension despite optimal medical management (per investigators assessment)\n4. Patient has poorly controlled diabetes (per investigators assessment)\n5. Patient is known to have an uncontrolled active systemic infection (\\>CTCAE grade 2) and recent infection requiring intravenous anti-infective treatment that was completed ≤14 days before the first dose of study drug\n6. Cerebrovascular accident, deep vein thrombosis or pulmonary embolism within 3 months before the start of study treatment\n7. Non-healing wound, ulcer or bone fracture in a short time\n8. Known bleeding diathesis or hemophilia\n9. Known history of infection with human immunodeficiency virus (HIV) or active stage of infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) . Active HBV infection must be confirmed by a positive test for HBV surface antigen or a positive test for hepatitis B core antibody with a positive determination of HBV DNA by polymerase chain reaction (PCR). For Hepatitis C virus (HCV), confirmation must be made by a positive test for HCV antibodies, unless the subject has been treated and has shown a sustained virological response. Note: Subjects with positive HCV antibodies who have been treated and have shown a sustained virological response (negative virus detection for at least 6 months after completing treatment) will not be excluded.\n10. Patient underwent major systemic surgery ≤ 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery\n11. Unable to swallow capsules or disease significantly affecting gastrointestinal function\n12. Life-threatening illness, medical conditions, or organ dysfunctions that may endanger the safety of the subject or put the study outcomes at risk.\n13. Lactating or pregnant\n14. Requires anticoagulation therapy with warfarin or equivalent vitamin K antagonists; requires treatment with potent CYP3A4\u002F5 inhibitors.\n15. Requires long-term use of dexamethasone ≥4mg\u002Fday or equivalent doses of corticosteroid formulations.\n16. Requires treatment with immunosuppressive agents, including cyclosporine A, tacrolimus, and sirolimus. Patients must discontinue the use of immunosuppressive agents 28 days before receiving study medication.",{"count":200,"type":19},30,[90],"This is a phase Ⅱ clinical study of Zanubrutinib(Z) in combination with methotrexate (M) and thiotepa(T) in treating newly diagnosed primary CNS lymphoma (PCNSL).\n\nThe purpose of the study is to test the efficacy and tolerability of a combination treatment of MTZ regimen in treating patients who have newly diagnosed PCNSL",[204,26],"Primary Central Nervous System Lymphoma (PCNSL)","2024-10-15",{"date":207,"type":40},"2024-10-17",{"date":209,"type":19},"2025-01-01",{"date":211,"type":19},"2028-01-01",{"name":213,"class":47},"Sun Yat-sen University",{"id":215,"slug":4,"hasResults":10,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":220,"targetDuration":222,"studyType":223,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":48},"100301053","NCT03199066","Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)","The Incidence, Epidemiology, Clinical Characteristic, Prognostic Factors, Therapy and Outcome of Non-Hodgkin Lymphoma Patients in the Czech Republic. NiHiL- Longitudinal Observational Study of Czech Lymphoma Study Group (CLSG)","Inclusion Criteria:\n\n* lymphoma diagnosis\n* treated in the Czech Republic\n* signed informed consent\n\nExclusion Criteria:\n\n* unsigned informed consent\n* age \\\u003C18 y",{"count":221,"type":19},20000,"10 Years","OBSERVATIONAL","The Czech National Lymphoma Registry (NiHiL) was founded to monitor epidemiologic data and improve the diagnostic evaluation and quality of treatment of patients with non-Hodgkin´s lymphoma (NHL).\n\nThe patients are registered into the registry in anonymized form. For each patient are available: registration form, diagnostic form, treatment form, follow- up form, and other malignancy form.\n\nData quality in the NiHiL has been checked by audits. The data is analyzed according to NHL subtypes with endpoints: lymphoma distribution, epidemiological data, prognostic characteristic, treatment characteristics, response rate, relapse rate, mortality, PFS, OS, DFS, Lymphoma specific survival, longterm toxicity.",[26],[227,228,229],"survival","therapy","epidemiology","2017-06-21",{"date":232,"type":40},"2017-06-26",{"date":234,"type":40},"1999-01-01",{"date":139,"type":19},{"name":237,"class":47},"Czech Lymphoma Study Group",""]